Literature DB >> 28342183

Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma.

Toby A Eyre1, Wendy L Osborne2, Eve Gallop-Evans3, Kirit M Ardeshna4, Shireen Kassam5, Shalal Sadullah6, Gamal Sidra7, Dominic Culligan8, Arvind Arumainathan9, Paneesha Shankara10, Kristian M Bowles11, David W Eyre12, Ying Y Peng13, Ruth Pettengell13, Adrian Bloor14, Elisabeth Vandenberghe15, Graham P Collins1.   

Abstract

Entities:  

Keywords:  PI3K; follicular lymphoma; idelalisib

Mesh：

Substances：

Year:  2017        PMID： 28342183     DOI： 10.1111/bjh.14665

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  5 in total

Review 1.  Novel Therapy Approaches to Follicular Lymphoma.

Authors:  Michael Northend; William Townsend
Journal:  Drugs       Date:  2021-03       Impact factor: 9.546

Review 2.  Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence.

Authors:  Monia Marchetti; Candida Vitale; Gian Matteo Rigolin; Alessandra Vasile; Andrea Visentin; Lydia Scarfò; Marta Coscia; Antonio Cuneo
Journal:  J Clin Med       Date:  2022-04-07       Impact factor: 4.964

Review 3.  Controversies in the Treatment of Follicular Lymphoma.

Authors:  Kai Hübel; Michele Ghielmini; Marco Ladetto; Ajay K Gopal
Journal:  Hemasphere       Date:  2020-01-10

4.  Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela Study.

Authors:  Beatrice Casadei; Lisa Argnani; Alessandro Broccoli; Caterina Patti; Piero Maria Stefani; Antonio Cuneo; Gloria Margiotta Casaluci; Carlo Visco; Guido Gini; Fabrizio Pane; Francesco D'Alò; Debora Luzi; Maria Cantonetti; Samantha Pozzi; Gerardo Musuraca; Chiara Rosignoli; Annalisa Arcari; Sofya Kovalchuk; Monica Tani; Maria Chiara Tisi; Mario Petrini; Vittorio Stefoni; Pier Luigi Zinzani
Journal:  Cancers (Basel)       Date:  2022-01-27       Impact factor: 6.639

5.  Comprehensive Molecular Profiling for Relapsed/Refractory Pediatric Burkitt Lymphomas-Retrospective Analysis of Three Real-Life Clinical Cases-Addressing Issues on Randomization and Customization at the Bedside.

Authors:  Kristyna Polaskova; Tomas Merta; Alexandra Martincekova; Danica Zapletalova; Michal Kyr; Pavel Mazanek; Zdenka Krenova; Peter Mudry; Marta Jezova; Jiri Tuma; Jarmila Skotakova; Ivana Cervinkova; Dalibor Valik; Lenka Zdrazilova-Dubska; Hana Noskova; Karol Pal; Ondrej Slaby; Pavel Fabian; Sarka Kozakova; Jakub Neradil; Renata Veselska; Veronika Kanderova; Ondrej Hrusak; Tomas Freiberger; Giannoula Lakka Klement; Jaroslav Sterba
Journal:  Front Oncol       Date:  2020-02-07       Impact factor: 6.244
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.